A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer - GeparSixto

German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)0 个研究点开始时间: 2011年5月3日最近更新: 2014年2月3日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•1.Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
•2.Complete baseline documentation must be submitted via Medcodes® and approved by GBG Forschungs GmbH.
•3.Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.
•4.Tumor lesion in the breast with a palpable size of = 2 cm or a sonographical size of = 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.
•5.Patients should be in the following stages of disease:
•- cT2 - cT4a-d or
•- cT1c and cN+ or pNSLN+
•6.In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.
•7.Centrally confirmed ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as >1% stained cells and HER2-positive is defined as HercepTest IHC 3+ or FISH ratio =2.2. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the Dept. of Pathology at the Charité, Berlin prior to randomization (4 cores and up to 8-10mm FFPE tumor need to be provided).
•8.Age = 18 years.
•9.Karnofsky Performance status index = 80%.
•10.Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. LVEF must be = 55%.
•11.Laboratory requirements:
•- Absolute neutrophil count (ANC) = 2.0 x 109 / L and
•- Platelets = 100 x 109 / L and
•- Hemoglobin = 10 g/dL (= 6.2 mmol/L)
•Hepatic function
•-Total bilirubin < 1.5x UNL and
•- ASAT (SGOT) and ALAT (SGPT) = 1.5x UNL and
•- Alkaline phosphatase = 2.5x UNL.
•Renal function
•- Creatinine = 175 µmol/L (2 mg/dL) < 1.5x UNL
•- Proteinuria: Urine dipstick for proteinuria < 2+. Patients discovered to have = 2+ proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must demonstrate = 1 g of protein in 24 hours.
•If creatinine is between 140 – 175 umol/L (1.6-2.0 mg/dL), the creatinine clearance (calculated or measured) should be = 45 mL/min.
•12.Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential.
•13.Complete staging work-up within 3 months prior to randomization. All patients must have bilateral mammography, breast ultrasound (= 21 days), breast MRI (optional), chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan done. In case of positive bone scan, bone X-ray (or CT or MRI) is mandatory. Other tests may be performed as clinically indicated.
•14.Patients must be available and compliant for central diagnostics, treatment and follow-up.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 600
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 600

排除标准

•1.Prior chemotherapy for any malignancy.
•2.Prior radiation therapy for breast cancer.
•3.Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment.
•4.Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based chemotherapy).
•5.Previous malignant disease without being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).
•6.Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >160 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
•7.Previous thromboembolic event (except when thrombophily screening is negative).
•8.Known hemorrhagic diathesis or coagulopathy with increased bleeding risk.
•9.History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
•10.Pre-existing motor or sensory neuropathy of a severity = grade 2 by NCI-CTC criteria v 4.0.
•11.Currently active infection.
•12.Active peptic ulcer.
•13.Incomplete wound healing or unhealed bone fracture.
•14.Disease significantly affecting gastrointestinal function, e.g. malabsorption syndrome, resection of the stomach or small bowel, ulcerative colitis.
•15.History of abdominal fistula or any grade 4 non-gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.
•16.Severe pulmonary condition / illness.
•17.Major surgery within the last 28 days or anticipation of the need for major surgery during study treatment with bevacizumab. No minor surgeries including insertion of an indwelling catheter or sentinel lymph node biopsy within 24 h prior to chemotherapy.
•18.Definite contraindications for the use of corticosteroids except inhalative corticoids.
•19.Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol;
•20.Concurrent treatment with:
•- chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (= 10 mg methylprednisolone or equivalent).
•- sex hormones. Prior treatment must be stopped before study entry.
•- virostatic agents like sorivudine or analogs like brivudine, concurrent treatment with aminoglycosides.
•- anticoagulants: heparin, warfarin as well as acetylic acid (e.g. Aspirin®) at a dose of > 325 mg/day or clopidogrel at a dose of > 75 mg/day.
•- other experimental drugs or any other anti-cancer therapy.
•- drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A, e.g. Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Telithromycin, Erythromycin, Verapamil, Diltiazem within the last 5 days or the expected need for these treatments during study participation.
•21.Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.
•22.Male patients.

研究者

发起方

German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)

相似试验

已完成

不适用

A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancer

ISRCTN30851756VU University Medical Center (The Netherlands)200

进行中（未招募）

1 期

A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)

EUCTR2012-000091-41-GBniversity College London57

进行中（未招募）

1 期

EUCTR2015-002714-72-DEGBG Forschungs GmbH174

进行中（未招募）

1 期

未命名试验

EUCTR2021-006331-26-FRICANCER150

已完成

2 期

A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer.advanced hepatobiliary and pancreatic cancer patients

JPRN-UMIN000015105Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology40